{"id":2191,"date":"2020-11-12T09:50:32","date_gmt":"2020-11-12T14:50:32","guid":{"rendered":"https:\/\/pa.cair.com\/pitt\/?p=2191"},"modified":"2020-11-12T10:03:13","modified_gmt":"2020-11-12T15:03:13","slug":"behind-pfizers-vaccine-an-understated-husband-and-wife-dream-team","status":"publish","type":"post","link":"https:\/\/pa.cair.com\/pitt\/behind-pfizers-vaccine-an-understated-husband-and-wife-dream-team\/","title":{"rendered":"Behind Pfizer’s vaccine, an understated husband-and-wife “dream team”"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Behind Pfizer's vaccine,
an understated husband-and-wife \"dream team\"<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

By Ludwig Burger<\/a>,Patricia Weiss<\/a><\/p>

FRANKFURT (Reuters) – Positive data on BioNTech and U.S. partner Pfizer Inc\u2019s COVID-19 vaccine is an unlikely success for the married couple behind the German biotech firm, who have devoted their lives to harnessing the immune system against cancer. Pfizer said on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study.\u00a0<\/p><\/div>

Pfizer and BioNTech are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.<\/p>

From humble roots as the son of a Turkish immigrant working at a Ford factory in Cologne, BioNTech Chief Executive Ugur Sahin, 55, now figures among the 100 richest Germans, together with his wife and fellow board member Oezlem Tuereci, 53, according to weekly Welt am Sonntag.<\/p>

The market value of Nasdaq-listed BioNTech, which the pair co-founded, had ballooned to $21 billion as of Friday\u2019s close from $4.6 billion a year ago, with the firm set to play a major role in mass immunisation against the coronavirus.<\/p>

\u201cDespite his achievements, he never changed from being incredibly humble and personable,\u201d said Matthias Kromayer, board member of venture capital firm MIG AG, whose funds have backed BioNTech since its inception in 2008.<\/p>

He added Sahin would typically walk into business meetings wearing jeans and carrying his signature bicycle helmet and backpack<\/p>

Doggedly pursuing his childhood dream of studying medicine and becoming a physician, Sahin worked at teaching hospitals in Cologne and the southwestern city of Homburg, where he met Tuereci during his early academic career.<\/p>

Medical research and oncology became a shared passion.<\/p>

Tuereci, the daughter of a Turkish physician who had migrated to Germany, said in a media interview that even on the day of their wedding, both made time for lab work.<\/p>

Together they honed in on the immune system as a potential ally in the fight against cancer and tried to address the unique genetic makeup of each tumour.<\/p>

Life as entrepreneurs started in 2001 when they set up Ganymed Pharmaceuticals to develop cancer-fighting antibodies, but Sahin – by then a professor at Mainz university – never gave up academic research and teaching.<\/p>

They won funding from MIG AG as well as from Thomas and Andreas Struengmann, who sold their generic drugs business Hexal to Novartis in 2005.<\/p>

That venture was sold to Japan\u2019s Astellas in 2016 for up to $1.4 billion. By then, the team behind Ganymed was already busy building BioNTech, founded in 2008, to pursue a much broader range of cancer immunotherapy tools.<\/p>

That included mRNA, a versatile messenger substance to send genetic instructions into cells.<\/p>

DREAM TEAM<\/h2>

For MIG\u2019s Kromayer, Tuereci and Sahin are a \u201cdream team\u201d in that they reconciled their visions with the constraints of reality.<\/p>

The BioNTech story took a twist when Sahin in January came across a scientific paper on a new coronavirus outbreak in the Chinese city of Wuhan and it struck him how small the step was from anti-cancer mRNA drugs to mRNA-based viral vaccines.<\/p>

BioNTech quickly assigned about 500 staff to project \u201clight speed\u201d to work on several possible compounds, winning pharma giant Pfizer and Chinese drugmaker Fosun as partners in March.<\/p>

Matthias Theobald, a fellow oncology professor at Mainz university who has worked with Sahin for 20 years, said his tendency towards understatement belies a relentless ambition to transform medicine, exemplified by the leap of faith to a COVID-19 vaccine.<\/p>

\u201cHe is a very modest and humble person. Appearances mean little to him. But he wants to create the structures that allow him to realise his visions and that\u2019s where is aspirations are far from modest,\u201d Theobald said.<\/p>

Sahin told Reuters on Monday the read-out amounted to an \u201cextraordinary success rate\u201d but that he did not know earlier in the year how difficult the task overall would be.<\/p>

\u201cIt\u2019s certainly not something that you would easily voice as a serious scientist, but it was within the realms of possibility from the beginning.\u201d<\/p>

Original article can be found here: https:\/\/www.reuters.com\/article\/health-coronavirus-biontech-ceo-newsmake-idUSKBN27P1O5<\/a><\/p>

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Behind Pfizer’s vaccine, an understated husband-and-wife “dream team” By Ludwig Burger,Patricia Weiss FRANKFURT (Reuters) – Positive data on BioNTech and U.S. partner Pfizer Inc\u2019s COVID-19 vaccine is an unlikely success for the married couple behind the German biotech firm, who have devoted their lives to harnessing the immune system against […]<\/p>\n","protected":false},"author":6,"featured_media":1511,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":"","_tec_slr_enabled":"","_tec_slr_layout":""},"categories":[8],"tags":[],"class_list":["post-2191","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-community-updates"],"ticketed":false,"_links":{"self":[{"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/posts\/2191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/comments?post=2191"}],"version-history":[{"count":3,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/posts\/2191\/revisions"}],"predecessor-version":[{"id":2194,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/posts\/2191\/revisions\/2194"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/media\/1511"}],"wp:attachment":[{"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/media?parent=2191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/categories?post=2191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pa.cair.com\/pitt\/wp-json\/wp\/v2\/tags?post=2191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}